TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Travere Therapeutics, Inc.
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$50.49+0.89 (+1.79%)
Close on Oct 19, 2026
- Market cap
- $4.72B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2026
Gross margin
97.9%+1.0 pts over 5 years
Operating margin
-12.8%+76.0 pts over 5 years
Net margin
-5.2%+80.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +110.5% | +64.9% | +19.9% | +17.3% | |
| Gross profit | +113.1% | +66.0% | +20.1% | +17.3% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -15.8% | -78.4% | -29.4% | |
| Return on assets | -9.2% | -28.0% | -4.3% | |
| Current ratio | 3.99 | 4.43 | 2.74 | |
| Interest coverage | -12.3× | -9.2× | -5.8× | |
| Inventory turnover | 1.7× | 0.9× | 0.3× | |
| Capex to revenue | 1.1% | 3.4% | – | |
| Diluted shares | 38M | 48M | 89M |
Cash use needs five years of cash flow figures
Travere Therapeutics does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-5.2%
×Asset turnover0.82×
×Equity multiplier6.90×
=Return on equity, FY2026-29.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -5.2% | 0.82× | 6.90× | -29.4% |
| FY2025 | -137.9% | 0.34× | 5.32× | -247.4% |
| FY2024 | -76.7% | 0.20× | 6.00× | -91.4% |
| FY2023 | -254.4% | 0.15× | 4.20× | -161.5% |
| FY2022 | -136.6% | 0.19× | 2.70× | -70.2% |
| FY2021 | -85.4% | 0.33× | 2.80× | -78.4% |
| FY2020 | -83.5% | 0.27× | 2.44× | -54.3% |
| FY2019 | -62.5% | 0.27× | 2.01× | -33.6% |
| FY2018 | -38.6% | 0.30× | 1.74× | -19.9% |
| FY2017 | -35.9% | 0.26× | 1.71× | -15.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
6of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$25.55M
- Cash generatingOperating cash flow above zero$37.78M
- Return on assets improvedROA up on the prior year-40.8% → -4.3%
- Earnings backed by cashOperating cash flow above net income$37.78M vs -$25.55M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.08 → 2.74
- No dilutionShare count did not rise79M → 89M
- Gross margin improvedGross margin up on the prior year96.68% → 97.89%
- More efficientAsset turnover rose0.30 → 0.83